Cerba Research brings together leading voices from across the clinical research landscape to unpack the evolving challenges in infectious disease R&D. This roundtable report features expert insights from Novavax, BioNTech, VIDO, F2G, and more, highlighting the operational and scientific realities facing today’s vaccine and therapeutic developers. As the post-COVID era reshapes expectations around timelines, funding, and public trust, the panel discusses how the industry can keep its momentum while adjusting to this new reality.

The report takes a close look at critical challenges, including AI integration, economic pressures affecting antibiotic development, and regulatory complexities in bringing combination vaccines to market. The panelists also address ongoing operational bottlenecks, such as delays in site contracting and the limitations of decentralized testing, while highlighting the need for early community engagement and unified data strategies to boost clinical trial preparedness and improve patient retention.

Access the report to gain insights on:

• Current roadblocks and innovations in infectious disease trials.
• Strategies for building public trust and improving participant retention.
• Trends in regulatory expectations, surveillance, and AI adoption.
• The future of vaccine development, from combined antigens to global harmonization.
• Real-world commentary from experts shaping the next generation of clinical R&D.

This essential read offers actionable perspectives for sponsors, CROs, and researchers who are navigating the rising complexity of infectious disease research.